
Advaxis bails on late-stage study of AXAL in cervical cancer; shares down 4% Seeking Alpha
Citing a sharpened focus on neoantigen-directed immunotherapies, Advaxis (ADXS -4.4%) announces that it will terminate its Phase 3 AIM2CERV trial …
“cervical cancer” – Google News
